Authors: Marlin, Romain; Godot, Veronique; Cardinaud, Sylvain; Galhaut, Mathilde; Coleon, Severin; Zurawski, Sandra; Dereuddre-Bosquet, Nathalie; Cavarelli, Mariangela; Gallouët, Anne-Sophie; Maisonnasse, Pauline; Dupaty, Léa; Fenwick, Craig; Naninck, Thibaut; Lemaitre, Julien; Gomez-Pacheco, Mario; Kahlaoui, Nidhal; Contreras, Vanessa; Relouzat, Francis; Ho Tsong Fang, Raphaël; Wang, Zhiqing; Ellis, Jerome; Chapon, Catherine; Centlivre, Mireille; Wiedemann, Aurelie; Lacabaratz, Christine; Surenaud, Mathieu; Szurgot, Inga; Liljeström, Peter; Planas, Delphine; Bruel, Timothée; Schwartz, Olivier; van Der Werf, Sylvie; Pantaleo, Giuseppe; Prague, Mélanie; Thiébaut, Rodolphe; Zurawski, Gerard; Lévy, Yves; Le Grand, Roger

Venue: Nature Communications

Type: Publication

Abstract: Abstract Achieving sufficient worldwide vaccination coverage against SARS-CoV-2 will require additional approaches to currently approved viral vector and mRNA vaccines. Subunit vaccines may have distinct advantages when immunizing vulnerable individuals, children and pregnant women. Here, we present a new generation of subunit vaccines targeting viral antigens to CD40-expressing antigen-presenting cells. We demonstrate that targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein to CD40 (αCD40.RBD) induces significant level... (read more)

Impact:   2.673856E-8    3.257218E-9    33    28  / Attention: 0 38

PubMed Id: 34471122